维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="Tayebjee MH"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of metalloproteinases(MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases(TIMP)-1 and -2显示文摘	Tayebjee MH Lip GY Blann AD	2005	Thrombosis Res2005，115，3：	1
2	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes : effect of 1 year's cardiovascular risk reduction therapy 显示文摘	Tayebjee MH Lira HS Macfadyen RJ	2004	Diabetes Care2004，27，8：	1
3	Right atrialflutter isthmus ablation is feasible and results in acute clinicalimprovement in patients with persistent atrial flutter and severepulmonary arterial hypertension显示文摘	Showkathali R Tayebjee MH Gibbs SR	2011	Int J Cardiol2011，1492，：	1
4	Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease 显示文摘	Lim HS Tayebjee MH Tan KT	2008	? Thromb Res2008，122，3：	1
5	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes : effect of 1 year's cardiovascular risk reduction therapy 显示文摘	Tayebjee MH Lira HS MacFadyen RJ	2004	Diabetes Care2004，27，：	1
6	Matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment : a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 显示文摘	Tayebjee MH Nadar S Blann AD	2004	Am J Hypertens2004，17，9：	1
7	Circulating Matrix metalloproteinases-9 and tissue inhibitors of metalloproteinases-1 and-2 levels in gestational hypertension 显示文摘	Tayebjee MH Karalis I Nadar SK	2005	Am J Hyper2005，18，3：	1
8	MacFadyen RJ Lip GY Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and -2 levels in gestational hypertension显示文摘	Tayebjee MH Karalis I Nadar SK	2005	Am J Hypertens2005，18，3：	1
9	Matrix metallopro teinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment:a sub-study of the Anglo-Scandinavian cardiac outcomes trial (ASCOT)显示文摘	Tayebjee MH Nadar S Blann AD	2004	Am J Hypertens2004，17，9：	1
10	Relation of platelet activation to coronary angiographic severity and collateralization 显示文摘	Tan KT Tayebjee MH Macfadyen RJ	2005	Am J Cardiol2005，96，2：	1
11	Matrix metallo- proteinases in coronary artery disease: clinical and ther- apeutic implications and pathological significance显示文摘	Tayebjee MH Lip H Gregory Y	2005	Cur- rent medicinal chemistry2005，12，8：	1
12	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)显示文摘	Tayebjee MH Nadar S Blann AD	2004	Am J Hypertens2004，17，9：	1
13	Target organ damage in hypertension:pathophysiology and implications for drug therapy显示文摘	Nadar SK Tayebjee MH Messerli F	2006	Curr Pharm Des2006，12，13：	1
14	Survey of antibiotic prophylaxis for implantahle cardiac electronic device (ICED) insertion in England 显示文摘	Lowe E Tayebjee MH Pratty J	2012	Int J Cardiol2012，157，2：	1
15	Matrix metalloproteinase -9 and tissue inhibitor of metallopreteinase - 1 in hypertension and their relationship to cardiovascular risk and treatment : a substudy of the Anglo - Scandinavian Cardiac Outcomes Trial ( ASCOT) 显示文摘	Tayebjee MH Nadar S Blann AD	2004	Am J Hypertens2004，17，9：	1
16	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy 显示文摘	Tayebjee MH Lim HS Macfadyen RJ	2004	Diabetes Care2004，27，8：	1
17	Clinically ap- parent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels显示文摘	Tan KT Tayebjee MH Lim HS	2005	Dia- bet Med2005，22，12：	1
18	Matrix metalloproteinases in coronary artery disease: clinical and therapeutie implications and pathological significance 显示文摘	Tayebjee MH Lip GY MaCFadyen RJ	2005	Curr Med Chem2005，12，8：	1
19	Can implantable cardiac electronic device infections be defined as 'early' or 'late' based on the cause of infection? 显示文摘	Tayebjee MH Joy ER Sandoe JA	2013	J Med Microbiol2013，62，8：	1
20	Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance显示文摘	Tayebjee MH Lip GY MacFadyen RJ	2005	Curr Med Chem2005，12，6：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示